Abstract
Ischemic heart disease remains a leading cause of morbidity and mortality in industrialized nations, and contributes substantially to healthcare expenditure worldwide. As the evidence base in acute coronary syndromes (ACS) has expanded dramatically over decades, longitudinal data demonstrate improvements in risk factor modification, organization of healthcare systems, and disease management that have substantially attenuated the adverse prognosis of both ST-segment elevation myocardial infarction (STEMI) and non-STsegment elevation ACS (NSTE-ACS). Nevertheless, discrepancies remain between genders, and women with ACS often sustain worse outcomes than men. In this review, we focus on the gender and sex-specific commonalities and differences in the pathophysiology, clinical presentations, diagnosis, and risk stratification of ACS. We highlight available data on the interactions between gender and efficacy of current pharmacological and interventional treatment for NSTE-ACS and STEMI. We also examine gender differences in the trends of clinical outcomes, and possible mechanisms that account for persistent care gaps where future efforts can be directed.
Keywords: Acute coronary syndromes, gender, outcomes, risk stratification, trends.
Current Pharmaceutical Design
Title:From Mars to Venus: Gender Differences in the Management and Outcomes of Acute Coronary Syndromes
Volume: 22 Issue: 25
Author(s): Nigel S. Tan and Andrew T. Yan
Affiliation:
Keywords: Acute coronary syndromes, gender, outcomes, risk stratification, trends.
Abstract: Ischemic heart disease remains a leading cause of morbidity and mortality in industrialized nations, and contributes substantially to healthcare expenditure worldwide. As the evidence base in acute coronary syndromes (ACS) has expanded dramatically over decades, longitudinal data demonstrate improvements in risk factor modification, organization of healthcare systems, and disease management that have substantially attenuated the adverse prognosis of both ST-segment elevation myocardial infarction (STEMI) and non-STsegment elevation ACS (NSTE-ACS). Nevertheless, discrepancies remain between genders, and women with ACS often sustain worse outcomes than men. In this review, we focus on the gender and sex-specific commonalities and differences in the pathophysiology, clinical presentations, diagnosis, and risk stratification of ACS. We highlight available data on the interactions between gender and efficacy of current pharmacological and interventional treatment for NSTE-ACS and STEMI. We also examine gender differences in the trends of clinical outcomes, and possible mechanisms that account for persistent care gaps where future efforts can be directed.
Export Options
About this article
Cite this article as:
Tan S. Nigel and Yan T. Andrew, From Mars to Venus: Gender Differences in the Management and Outcomes of Acute Coronary Syndromes, Current Pharmaceutical Design 2016; 22 (25) . https://dx.doi.org/10.2174/1381612822666160328113831
DOI https://dx.doi.org/10.2174/1381612822666160328113831 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurohormonal Activation in Ischemic Stroke: Effects of Acute Phase Disturbances on Long-Term Mortality
Current Neurovascular Research MicroRNA Therapeutics for Cardiac Regeneration
Mini-Reviews in Medicinal Chemistry The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries
Current Vascular Pharmacology The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology Studies on Growth Kinetics of Serratia marcescens VITSD2 and Optimization of Fermentation Conditions for Serratiopeptidase Production
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection
Reviews on Recent Clinical Trials Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Analysis of QTc Interval during Levofloxacin Prescription in Cardiac Patients with Pneumonia
Current Drug Safety The Cellular and Molecular Basis of Health Benefits of Grape Seed Proanthocyanidin Extract
Current Pharmaceutical Biotechnology Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Atherosclerosis and Inflammation: Insight from Carotid and Intracoronary Ultrasound Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial: The Interplay between TSH and Lipids. What Should Clinicians Know?
Current Vascular Pharmacology